Mometahexal (Mometasone Furoate)

Mometasone furoate acts as a glucocorticoid receptor agonist. After binding to intracellular receptors, it alters gene transcription, suppressing the release of inflammatory cytokines and chemokines. This reduces inflammatory cell infiltration and edema in the nasal mucosa, leading to symptom relief.

The appropriate dose of Mometahexal is determined by the prescribing healthcare professional based on the patient’s age, severity of symptoms, and clinical response. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. Healthcare providers usually weigh the potential benefits against any possible risks. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss use with their physician.

To request Mometahexal, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mometahexal contains mometasone furoate, a high‑potency intranasal corticosteroid with minimal systemic absorption when used at recommended doses. Compared with older agents such as beclomethasone, it often provides comparable or superior symptom control with a lower risk of systemic side effects.

Store Mometahexal at room temperature, preferably below 25 °C. Keep the spray in its original packaging, protect it from moisture and direct heat, and ensure the cap is tightly closed when not in use.

Mometahexal is administered as a nasal spray. The patient should gently blow the nose, insert the nozzle into one nostril, and spray the prescribed number of sprays while breathing in gently. The process is repeated in the other nostril if directed by the prescriber.

Serious but rare risks include nasal septal perforation, severe allergic reactions such as anaphylaxis, adrenal suppression with prolonged high‑dose use, and opportunistic fungal infections of the nasal cavity. Patients should seek immediate medical attention if they notice unusual bleeding, persistent pain, or signs of systemic steroid effects.

Mometahexal should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It is also contraindicated in patients with active untreated nasal infections, recent nasal surgery, or trauma until healing is complete.